Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EVALUATION OF THE TREATMENT RESPONSE OF LUNG-CANCER WITH POSITRON EMISSION TOMOGRAPHY AND L-[METHYL-C-11]METHIONINE - A PRELIMINARY-STUDY
Autore:
KUBOTA K; YAMADA S; ISHIWATA K; ITO M; FUJIWARA T; FUKUDA H; TADA M; IDO T;
Indirizzi:
TOHOKU UNIV,DEPT RADIOL & NUCL MED,CANC TUBERCULOSIS RES INST,4-1 SEIRYO CHO SENDAI MIYAGI 980 JAPAN TOHOKU UNIV,DEPT PHARMACOL,CANC & TUBERCUL RES INST,AOBA KU SENDAI MIYAGI 980 JAPAN TOHOKU UNIV,CTR CYCLOTRON & RADIOISOTOPE SENDAI MIYAGI 980 JAPAN
Titolo Testata:
European journal of nuclear medicine
fascicolo: 6, volume: 20, anno: 1993,
pagine: 495 - 501
SICI:
0340-6997(1993)20:6<495:EOTTRO>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
F-18 FLUORODEOXYGLUCOSE; TUMOR UPTAKE; RADIOTHERAPY; PET; METHIONINE; THERAPY; FLUORINE-18-FLUORODEOXYGLUCOSE; METABOLISM; DIAGNOSIS; LYMPHOMA;
Keywords:
POSITRON EMISSION TOMOGRAPHY; LUNG CANCER; COMPUTED TOMOGRAPHY; C-11 METHIONINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
29
Recensione:
Indirizzi per estratti:
Citazione:
K. Kubota et al., "EVALUATION OF THE TREATMENT RESPONSE OF LUNG-CANCER WITH POSITRON EMISSION TOMOGRAPHY AND L-[METHYL-C-11]METHIONINE - A PRELIMINARY-STUDY", European journal of nuclear medicine, 20(6), 1993, pp. 495-501

Abstract

We carried out a study to evaluate treatment response and residual mass in lung cancer with positron emission tomography (PET), using L-[methyl-C-11] methionine (MET). MET tumour uptake and tumour volume measured by computed tomography (CT) before and within 2 weeks after radiotherapy or chemoradiotherapy were compared in 43 studies of 21 patients. Ten patients with local control (no recurrence) of tumour showed a larger decrease in MET uptake (65.2% +/- 12.2%) than in tumour volume (50.8% +/- 9.6%, P<0.01). Five patients with early recurrence (from 1 to 4 months) showed smaller decreases in both MET uptake (22.2% +/- 13.5%) and tumour volume (28.6% +/- 20.0%) than those in the no-recurrence group (P<0.01). Four patients with late recurrence (after 11 months or more) showed a similar decrease to the no-recurrence group in MET uptake (72.8% +/- 14.8%) but little change in tumour volume (18.5% +/- 19.0%), the latter result corresponding to that in the early-recurrence group. Using tumour volume only, the no-recurrence group was differentiated from both the early- and the late-recurrence group (P<0.01), but the early-recurrence group was not differentiated from the late-recurrence group. Using the MET uptake data, the early-recurrence group was clearly distinguished from the late-recurrence group (P<0.01), but the late-recurrence group was indistinguishable from the no-recurrencegroup. CT was useful in distinguishing the no-recurrence group from the groups in which there was ultimate recurrence, whether early or late. When a residual mass is seen on CT, PET seems to be helpful in evaluating tumour viability.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/21 alle ore 13:43:33